Sepsis is the body’s response to an infection. Existing diagnostic testing equipment is not available in primary care settings and requires long waiting times. Lateral flow devices (LFDs) could be employed in point-of-care (POC) settings for sepsis detection; however, they currently lack the required sensitivity. Herein, LFDs are constructed using 150–310 nm sized selenium nanoparticles (SeNPs) and are compared to commercial 40 nm gold nanoparticles (AuNPs) for the detection of the sepsis biomarker interleukin-6 (IL-6). Both 310 and 150 nm SeNPs reported a lower limit of detection (LOD) than 40 nm AuNPs (0.1 ng/mL compared to 1 ng/mL), although at the cost of test line visual intensity. This is to our knowledge the first use of larger SeNPs (>100 nm) in LFDs and the first comparison of the effect of the size of SeNPs on assay sensitivity in this context. The results herein demonstrate that large SeNPs are viable alternatives to existing commercial labels, with the potential for higher sensitivity than standard 40 nm AuNPs.
|Number of pages||8|
|Early online date||23 Feb 2023|
|Publication status||Published online - 23 Feb 2023|
Bibliographical noteFunding Information:
This project has been funded by Innovate UK and Invest NI as a Knowledge Transfer Partnership between Biopanda Reagents Ltd. and Ulster University (KTP12316) and the Royal Society International Cost Share Award IEC\R3\193004.
The authors would like to acknowledge and thank Innovate UK, Invest NI, and the Royal Society for providing funds for this work.
© 2023 The Authors. Published by American Chemical Society
- General Chemical Engineering
- General Chemistry